We are a genetic medicines company with a mission to make transformative therapies that are accessible to patients everywhere. We use our immune-silent single-stranded DNA (ssDNA) platform to design in vivo CAR-T and other gene therapies that break through the limitations of viral vectors and mRNA.
Making therapies accessible, affordable, and redosable.
At CPTx, we build therapeutics from the molecule up. Using precision-engineered ssDNA and non-viral lipid nanoparticle delivery systems, we enable durable expression, repeat dosing, and immune silence, without the complexity or toxicity of viral vectors or mRNA.
We are not just transforming how CAR-T therapies and genetic medicines are delivered. We are redefining what they can do.
In vivo CAR-T therapies have the potential to democratize cancer treatment, making cell therapy faster to develop, safer to administer, and easier to scale. We use our ssDNA platform to encode CARs directly with programmable payloads, modular control, and scalable delivery. Our platform has matured through years of research and now powers a growing therapeutic pipeline.
From concept to clinic, and beyond.
Building a new foundation for genetic medicines.
Our non-viral vector system is the result of many years of internal development, from fundamental manufacturing of high-quality gene-length ssDNA to engineering functional ssDNA structures to in vivo proof of concept. We have validated immune-silent biodistribution, broad tissue access, and gene expression in small animals, and we are advancing toward clinical translation with our lead pipeline programs.
Through gxstrands, our internal CDMO, we manufacture custom, high-sequence-fidelity ssDNA constructs up to 12kb and beyond, at scales ranging from micrograms to grams. We work with partners to power advanced research and clinical programs in parallel with our own.
We are building a future where genetic medicines are more accessible and more broadly applicable.
From programmable DNA to scalable delivery, CPTx is opening new doors for cancer treatments and novel gene therapies. Let’s build new medicines together.
